FDA Clearance Tracker · P000014
VITROS IMMUNODIAGNOSTIC PRODUCTS:ANTI-HBS REAGENT PACK/ANTI-HBS CALIBRATORS
Last checked: Nov 20, 2026Latest source record: Sep 29, 2000 (this decision)Source: openFDAMethods & limitations
Decided
Sep 29, 2000
Approved (reclassified)
Time to decision
211 days
Received Mar 2, 2000. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class II
The decision
- FDA number
- P000014
- Device name
- VITROS IMMUNODIAGNOSTIC PRODUCTS:ANTI-HBS REAGENT PACK/ANTI-HBS CALIBRATORS
- Applicant
- Ortho-Clinical Diagnostics, Inc.
- Applicant location
- Rochester, NY
- Received
- Mar 2, 2000
- Decided
- Sep 29, 2000
- Decision
- Approved (reclassified)
- Supplements
- 36 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class II
- Regulation
- 21 CFR 866.3173
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE VITROS IMMUNODIAGNOSTIC PRODUCTS ANTI-HBS REAGENT PACK AND CALIBRATORS. THE DEVICE IS INDICATED FOR: THE QUALITATIVE IN VITRO DETERMINATION OF TOTAL ANTIBODY TO HEPATITIS B SURFACE ANTIGEN (ANTI-HBS) IN HUMAN SERUM USING THE VITROS ECI IMMUNODIAGNOSTIC SYSTEM. ASSAY RESULTS MAY BE USED AS AN AID IN THE DETERMINATINO OF SUSCEPTIBILITY TO HEPATITIS B VIRUS (HBV) INFECTION FOR INDIVIDUALS PRIOR TO OR FOLLOWING HBV VACCINATION, OR WHERE VACCINATION STATUS IS UNKNOWN. ASSAY RESULTS MAY BE USED WITH OTHER HBV SEROLOGICAL MARKERS FOR THE LABORATORY DIAGNOSIS OF HBV DISEASE ASSOCIATED WITH HBV INFECTION. A REACTIVE ASSAY RESULT WILL ALLOW A DIFFERENTIAL DIAGNOSIS IN INDIVIDUALS DISPLAYING SIGNS AND SYMPTOMS OF HEPATITIS IN WHOM ETIOLOGY IS UNKNOWN.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- This is the earliest decision in FDA's data under product code SEI (Qualitative and Quantitative Hepatitis B Virus Antibody assays).
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Ortho-Clinical Diagnostics, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K254262 · Decided Sep 4, 2026 · 248 days after receipt
Device type: Devices Detecting Influenza A, B, And C Virus Antigens (PSZ) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.